Lupus & antiphospholipid syndrome
Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)
Authors' conclusion
This study provides valuable insights into PCP prophylaxis practices in patients with SLE in Japan, underscoring the importance of GC dosage and concomitant immunosuppressant use.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE) in the Lupus Registry of Nationwide Institutions in Japan, 2016–2021
- Participants
- 1,460 patients
- Exposure
- Prednisolone (PSL) dose categories vs PSL < 5 mg
- Outcome
- Prevalence of PCP prophylaxis and its association with GC dosage
Methodological detailsregistry-based, multivariate logistic regression, decision tree analysis
- Registry-based
- Multivariate logistic regression
- Decision tree analysis
Main finding
As reported in the abstract
PCP prophylaxis
aOR
- 5 ≤ PSL < 7.5 mg
- 3.7
- 7.5 ≤ PSL < 10 mg
- 5.2
- 10 ≤ PSL < 20 mg
- 9.0
- PSL ≥ 20 mg
- 43.1
- Patients who underwent PCP prophylaxis
- 21%
Observational data: associations, not effects.
Further findings
Determinants of PCP prophylaxis (decision tree analysis)
- PSL dosage < 11 mg/day and immunosuppressant use were key determinants
Original publication
Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA). Arthritis Res Ther. Published 12 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →